Baricitinib is an oral Janus kinase (JAK) inhibitor.
Baricitinib Emergency Use Authorization Timeline
Evaluation for COVID-19
Baricitinib: an emergency use treatment option for certain hospitalized patients with COVID-19.
Meet James – a 58-year-old man diagnosed with COVID-19
- Diagnosed with COVID-19
- Requires supplemental oxygen
Initial Treatment Decisions:
- Receiving local standard of care
Consider adding baricitinib to his treatment regimen.
SELECT IMPORTANT SAFETY INFORMATION RELATED TO SERIOUS INFECTIONS AND THROMBOSIS
Serious Infections: There is limited information regarding use of baricitinib in patients with COVID-19 and concomitant active serious infections.
Serious infections have occurred in patients receiving baricitinib. Avoid the use of baricitinib with known active tuberculosis. Consider if the potential benefits outweigh the potential risks of baricitinib treatment in patients with active serious infections other than COVID-19 or chronic/recurrent infections.
Thrombosis: In hospitalized patients with COVID-19, prophylaxis for venous thromboembolism is recommended unless contraindicated. If clinical features of deep vein thrombosis or pulmonary embolism occur, patients should be evaluated promptly and treated appropriately.
The pharmacokinetics in patients with COVID-19 who are intubated and have baricitinib administered via NG tube is similar to that in healthy subjects. The half-life of baricitinib in healthy subjects is approximately 10 hours.6